Avalyn Pharma (AVLN) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.14 billion vs $1.12 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | LBRX |
|---|---|---|
| Share price | $25.72 | $34.61 |
| Market cap | $1.14B | $1.12B |
| 1-day change | +0.74% | +1.32% |
| YTD return | — | +55.48% |
| 1-year return | — | +130.12% |
| P/E ratio (TTM) | — | 346.10 |
| EPS (TTM) | $-2.47 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $50.16 |
| 52-week low | $24.14 | $14.32 |
| Distance from 52-week high | -35.97% | -31.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +140.28% | +65.56% |
| Average volume | 245.04K | 341.17K |
| Shares outstanding | 44.33M | 32.26M |
| Employees | 55 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
AVLN vs LBRX FAQ
Which is bigger, Avalyn Pharma or LB Pharmaceuticals?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.14B compared with $1.12B for LB Pharmaceuticals (LBRX).
Are Avalyn Pharma and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.